



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Zenocutuzumab

Cat. No.:	HY-P99507
CAS No.:	1969309-56-5
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3 ^[1] .																	
In Vitro	<p>Zenocutuzumab (0.001-1000 nM; 96 hours) inhibits cell growth in lung and breast cancer cell lines^[1]. Zenocutuzumab (0.1-1000 nM; 24 hours) inhibits HER3 and AKT phosphorylation, induces markers of apoptosis and cell cycle arrest in lung and breast cancer cell lines^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human bronchiolar epithelial cell lines (HBEC)</td> </tr> <tr> <td>Concentration:</td> <td>0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>96 h</td> </tr> <tr> <td>Result:</td> <td>Reduced the growth of isogenic HBEC expressing either CD74-NRG1 or VAMP2-NRG1 fusions.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HBEC-CD74-NRG1, LUAD-0061AS3, MDA-MB-175-VII cells</td> </tr> <tr> <td>Concentration:</td> <td>0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited HER3, STAT3, AKT, p70S6K, and S6 phosphorylation.</td> </tr> </table>		Cell Line:	Human bronchiolar epithelial cell lines (HBEC)	Concentration:	0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM	Incubation Time:	96 h	Result:	Reduced the growth of isogenic HBEC expressing either CD74-NRG1 or VAMP2-NRG1 fusions.	Cell Line:	HBEC-CD74-NRG1, LUAD-0061AS3, MDA-MB-175-VII cells	Concentration:	0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM	Incubation Time:	24 hours	Result:	Inhibited HER3, STAT3, AKT, p70S6K, and S6 phosphorylation.
Cell Line:	Human bronchiolar epithelial cell lines (HBEC)																	
Concentration:	0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM																	
Incubation Time:	96 h																	
Result:	Reduced the growth of isogenic HBEC expressing either CD74-NRG1 or VAMP2-NRG1 fusions.																	
Cell Line:	HBEC-CD74-NRG1, LUAD-0061AS3, MDA-MB-175-VII cells																	
Concentration:	0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM																	
Incubation Time:	24 hours																	
Result:	Inhibited HER3, STAT3, AKT, p70S6K, and S6 phosphorylation.																	
In Vivo	<p>Zenocutuzumab (2.5-25 mg/kg; i.p.; once weekly; for 28 days) causes a statistically significant reduction of growth, including tumor regression^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>6 to 12-week-old female NSG™ (LUAD-0061AS3), BALB/c nude (OV-10-0050) or athymic</td> </tr> </table>		Animal Model:	6 to 12-week-old female NSG™ (LUAD-0061AS3), BALB/c nude (OV-10-0050) or athymic														
Animal Model:	6 to 12-week-old female NSG™ (LUAD-0061AS3), BALB/c nude (OV-10-0050) or athymic																	

	nude (ST2891, ST3204 and CTG-0953) mice injected with NRG1 fusion-positive patient-derived xenograft (PDX) tumors ^[1] .
Dosage:	2.5 mg/kg, 8 mg/kg, or 25 mg/kg
Administration:	i.p.; once weekly; for 28 days
Result:	Blocked growth of lung and ovarian cancer PDX models.

REFERENCES

[1]. Alison M Schram, et al. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. *Cancer Discov.* 2022 May 2;12(5):1233-1247.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA